Date: November 10, 2001
Location: Philadelphia, Pennsylvania, USA
Sponsors: Linda Creed Breast Cancer Foundation and the Center for Integrative Medicine at Thomas Jefferson University Hospital
Objectives: To discover and integrate alternative therapies into one's lifestyle and healing practices
Who should attend: Anyone with chronic illness, especially cancer of any kind, and anyone interested in learning about new therapies for health and healing
Topics: Integrative medicine, patient empowerment, integrating mind, body and spirit in the service of deeper healing. Workshop topics include: massage; mind-body therapy; mindfulness meditation; nutrition; oriental medicine; spirituality and healing; t'ai chi chuan; and western herbs.
Agenda: Keynote speaker: Joan Borysenko, Ph.D., internationally-renowned pioneer in integrative medicine and President of Mind/Body Health Sciences in Boulder, CO. Dr. Borysenko is Co-Founder and former Director of the Mind/Body Clinic at the Beth Israel/Deaconess Hospital in Boston and former Instructor in Medicine at the Harvard Medical School.
The agenda also includes speeches by Dr. Steven Rosenzweig, Founding Director of the Center for Integrative Medicine at Thomas Jefferson University Hospital and Dr. Marie Savard, Founder of Savard Systems and former Director of the Center for Women's Health, Associate Professor of the Medical College of Pennsylvania/Hahnemann University and the World Health Organization's technical advisor to the United Nations Fourth Annual World Conference on Women in Beijing.
The agenda includes four 45-minute experiential workshops on various alternative therapies (see "topics covered" for details).
Registration Info: Call the Linda Creed Breast Cancer Foundation at 215-545-0800 for registration information. Workshop registration required.
Fees: $35 per person, lunch included
Continuing Education: No
Sep 1, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.
Sep 1, 2014
Dec 13, 2010